Investment Rating - The investment rating for the company is "Accumulate" (maintained) [3] Core Views - The company reported a revenue of 925 million yuan for 2024, representing a year-on-year growth of 9.1%, and a net profit attributable to shareholders of 317.8 million yuan, up 2.5% year-on-year [5] - The company is expected to achieve revenue of 1,033 million yuan in 2025, with a growth rate of 11.6%, and a net profit of 351.9 million yuan, reflecting a growth of 10.7% [5] - The company maintains a strong market position with over 80% market share in the domestic allergy treatment sector, and its product pipeline continues to expand [5] Financial Performance Summary - For 2024, the company achieved a gross margin of 95.16% and a stable expense ratio, with sales expense ratio at 39.06% [5] - The company’s R&D expenses for 2024 were 120 million yuan, accounting for 12.95% of revenue [5] - The earnings per share (EPS) for 2024 is projected to be 0.61 yuan, with a P/E ratio of 34.5 [3][5] Revenue and Profit Forecast - The forecasted revenues for 2025-2027 are 1,033 million yuan, 1,171 million yuan, and 1,354 million yuan, respectively, with corresponding year-on-year growth rates of 11.6%, 13.3%, and 15.7% [5] - The net profit forecast for the same period is 351.9 million yuan, 394.0 million yuan, and 450.2 million yuan, with growth rates of 10.7%, 12.0%, and 14.3% [5] Product Pipeline and Market Expansion - The company has successfully expanded its product matrix, with new products such as "Skin Prick Test Solutions" receiving approval for market entry [5] - The company is actively promoting its products in northern markets, leading to significant sales increases, particularly for the Dust Mite Drops and Artemisia Pollen Drops [5]

Core Viewpoint - The company reported steady revenue growth and a continuous expansion of its core product matrix, with a positive outlook for future performance driven by increased market penetration and new product launches [1][2][4]. Financial Performance - In 2024, the company achieved operating revenue of 925 million yuan, a year-on-year increase of 9.10%, and a net profit attributable to shareholders of 318 million yuan, up 2.46% [1]. - For Q1 2025, the company reported operating revenue of 228 million yuan, a year-on-year increase of 5.65%, but a net profit decrease of 3.71% to 74 million yuan [1][2]. Product Performance - The company’s core products, particularly the dust mite drops, showed strong sales, generating 886 million yuan in 2024, a growth of 7.86% [2]. - The yellow flower pollen drops saw significant growth, with revenue reaching 27.01 million yuan in 2024, a year-on-year increase of 76.43%, driven by enhanced marketing efforts in northern markets [2]. - The skin prick solution also performed well, with revenue of 7.30 million yuan, reflecting a growth of 103.08% [2]. R&D and Product Pipeline - The company has expanded its product pipeline, with eight skin prick products approved for market launch and ongoing clinical trials for new drugs [2]. - The "house dust mite membrane agent" is entering Phase I clinical trials, while a new chemical drug is in Phase II [2]. Profitability and Cost Management - The overall gross margin remained stable at 95.16% in 2024 and 94.76% in Q1 2025 [3]. - The sales expense ratio increased to 39.06% in 2024 and 40.37% in Q1 2025, attributed to increased promotional activities [3]. - R&D expenses were 120 million yuan in 2024, reflecting a 6.85% increase, with a R&D expense ratio of 12.95% [3]. Future Outlook - Revenue projections for 2025-2027 are set at 1.033 billion, 1.171 billion, and 1.354 billion yuan, with expected growth rates of 11.6%, 13.3%, and 15.7% respectively [4]. - Net profit forecasts for the same period are 352 million, 394 million, and 450 million yuan, with growth rates of 10.7%, 12.0%, and 14.3% [4]. - The company maintains a leading market share of over 80% in the domestic allergy treatment market, with a strong outlook for continued growth [4].

关于浙江我武生物科技股份有限公司 2024 年年度股东会的法律意见书 致：浙江我武生物科技股份有限公司 上海礼丰律师事务所(以下简称"本所")接受浙江我武生物科技股份有限公司 (以下简称"公司")的委托，指派本所律师(以下简称"本所律师")根据《中华人民共 和国证券法》《中华人民共和国公司法》《上市公司股东会规则》等法律、法规、 规范性文件(以下统称"法律法规")及《浙江我武生物科技股份有限公司章程》(以 下简称"公司章程")的规定就公司 2024 年年度股东会(以下简称"本次股东会")相 关事宜出具法律意见。 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法》和《律师事务所证券法律业务执业规则(试行)》等规定及法律意 见书出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽 责和诚实信用原则，进行了充分的核查验证，保证法律意见所认定的事实真实、 准确、完整、及时，所发表的结论性意见合法、准确，不存在虚假记载、误导性 陈述或者重大遗漏，并承担相应法律责任。 本所律师已经按照有关法律法规的要求和律师行业公认的道德标准以及勤 勉尽责的精神对公司本次股东会相关文件及事实 ...

1. 本次股东会没有出现否决议案的情况； 2. 本次股东会不涉及变更以往股东会已通过决议的情况。 2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 一、会议召开和出席情况 1. 会议召集人：浙江我武生物科技股份有限公司（以下简称"公司"）董事会 2. 会议召开时间： 证券代码：300357 证券简称：我武生物 公告编号：2025-020 号 浙江我武生物科技股份有限公司 （1）现场会议召开时间：2025 年 5 月 23 日（星期五）下午 14:00 （2）网络投票时间：2025 年 5 月 23 日 其中，通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 23 日 9:15- 9:25、9:30-11:30 和 13:00-15:00；通过深圳证券交易所互联网投票系统进行网络投票的 具体时间为 2025 年 5 月 23 日 9:15-15:00。 3. 会议召开方式：采用现场表决与网络投票相结合的方式召开 4. 现场会议地点：上海市徐汇区钦江路 333 号 40 号楼 6 楼会议室 5. 会议主 ...

Core Insights - Zhejiang Iwu Biological Technology Co., Ltd. has made significant progress in the field of allergic disease diagnostics with the approval of its "Dermatitis Diagnostic Patch 02" for clinical trials by the National Medical Products Administration [1][5] Group 1: Product Development - The "Dermatitis Diagnostic Patch 02" focuses on diagnosing three common allergens: Kathon, p-phenylenediamine, and formaldehyde, which are frequently encountered in daily life and are known to cause allergic contact dermatitis [4][6] - The clinical trial process will follow a rigorous drug development protocol, including Phase I, II, and III trials to assess safety, efficacy, and dosage [5][6] Group 2: Market Position and Impact - Iwu Biological is a leading domestic pharmaceutical company specializing in the research and innovation of allergic disease diagnostics and treatments, with a strong R&D team and a history of successful product launches [6][7] - The approval of the "Dermatitis Diagnostic Patch 02" is expected to enhance the company's competitiveness in the diagnostic market and contribute to the development of the allergic disease diagnostics sector in China [6][7]

浙江我武生物科技股份有限公司 关于获得皮炎诊断贴剂 02 贴药物临床试验批准 通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 日前，浙江我武生物科技股份有限公司（以下简称"公司"）从国家药品监 督管理局政务服务门户网站下载获得《药物临床试验批准通知书》（通知书编号： 2025LP01362、2025LP01363、2025LP01364），由公司提交的"皮炎诊断贴剂 02 贴"（以下简称"本品"）药物临床试验申请获得批准。现将有关内容公告 如下： 一、基本情况 产品名称：皮炎诊断贴剂02贴 注册分类：治疗用生物制品1类 申请事项：境内生产药品注册临床试验 剂型：贴剂 证券代码：300357 证券简称：我武生物 公告编号：2025-019 号 申请适应症：用于斑贴试验，辅助诊断与卡松、对苯二胺、甲醛致敏相关的 变应性接触性皮炎。 药品注册申请人：浙江我武生物科技股份有限公司 根据《中华人民共和国药品管理法》及有关规定，经审查，皮炎诊断贴剂02 贴临床试验申请符合药品注册的有关要求，同意开展临床试验。 二、后续流程 本品获得《药物临床试验批准通知书》 ...

Group 1 - The controlling shareholder, WoW Consulting, plans to reduce its stake in WoW Bio (300357) by up to 4.5 million shares through block trading, representing 0.86% of the total share capital [1] - The actual controller, Hu Gengxi, will be the buyer of the shares being sold [1] - The company's director and deputy general manager, Zhang Lu, intends to reduce his holdings by up to 300,000 shares through centralized bidding, accounting for 0.06% of the total share capital [1] Group 2 - The reasons for the share reductions are stated as funding needs [1]

Group 1 - The controlling shareholder of the company plans to reduce its stake by up to 4.5 million shares through block trading, representing 0.86% of the total share capital [1] - The company's director and deputy general manager, Zhang Lu, intends to sell up to 300,000 shares through centralized bidding, accounting for 0.06% of the total share capital [1] - The reduction plan will not lead to a change in the company's control or affect its governance structure and ongoing operations [1]

证券代码：300357 证券简称：我武生物 公告编号：2025-018 号 浙江我武生物科技股份有限公司 关于控股股东与实际控制人之间通过大宗交易方式转让公司股 份以及董事、高级管理人员减持股份的预披露公告 股东浙江我武管理咨询有限公司、胡赓熙、张露保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 直接持有浙江我武生物科技股份有限公司（以下简称"公司"）203,454,131 股（占公司总股本比例 38.86%）的控股股东浙江我武管理咨询有限公司（以下 简称"控股股东"或"我武咨询"）计划自本公告披露日起 15 个交易日后的 3 个月内以大宗交易方式减持公司股份不超过 4,500,000 股（含本数），即不超过公 司总股本比例 0.86%。我武咨询本次通过大宗交易方式减持公司股份的受让方为 公司实际控制人之一的胡赓熙先生。 公司董事、副总经理张露女士直接持有公司股份 1,800,000 股（占公司总股 本的 0.34%），计划自本公告披露日起 15 个交易日后的 3 个月内以集中竞价交易 方式减 ...

3、涉案的金额：10,961,305.35 元及利息 3,215,093.51 元（暂计） 4、对上市公司损益产生的影响：因本次诉讼尚在审理中，目前无法预计对 公司本期及期后损益或所有者权益的影响。 证券代码：300357 证券简称：我武生物 公告编号：2025-017 号 浙江我武生物科技股份有限公司 关于公司涉及诉讼事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、案件所处的诉讼阶段：一审，审理中 2、上市公司所处的当事人地位：原告 浙江我武生物科技股份有限公司（以下简称"公司"或"原告"）已就上海 利合股权投资合伙企业（有限合伙）违反承诺减持公司股票事项向上海市浦东新 区人民法院（以下简称"法院"）提起诉讼，并于 2024 年 7 月 5 日收到法院发 出的立诉前调解案号为（2024）沪 0115 民诉前调 66428 号的通知，详见公司在 深圳证券交易所网站和符合中国证监会规定条件的媒体上于 2024 年 7 月 8 日披 露的《关于公司涉及诉讼的公告》（公告编号：2024-017 号）。2024 年 9 月 6 日， ...